U.S. markets closed

RxSight, Inc. (RXST)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
15.18+1.10 (+7.81%)
At close: 04:00PM EDT
15.18 0.00 (0.00%)
After hours: 04:01PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close14.08
Bid10.00 x 800
Ask16.89 x 800
Day's Range14.04 - 15.29
52 Week Range8.80 - 19.67
Avg. Volume96,993
Market Cap417.527M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.05
Earnings DateMay 05, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for RXST

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • RxSight, Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
  • Simply Wall St.

    RxSight, Inc. (NASDAQ:RXST) Just Reported, And Analysts Assigned A US$18.40 Price Target

    RxSight, Inc. ( NASDAQ:RXST ) shareholders are probably feeling a little disappointed, since its shares fell 7.5% to...

  • Motley Fool

    RxSight, Inc. (RXST) Q1 2022 Earnings Call Transcript

    Presenting today are RxSight president and chief executive officer, Ron Kurtz; and chief financial officer, Shelley Thunen. The strength in new LDD placements reflects, in part, the increasing productivity of our expanded LDD sales force.

  • GlobeNewswire

    RxSight, Inc. Reports First Quarter 2022 Financial Results

    ALISO VIEJO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three months ended March 31, 2022. Key Quarterly Highlights: Delivered first quarter 2022 revenue of $8.9 million, an increase of 157% compared to the first quarter of 2021, reflecting: The sale of 40 Light Delivery Devices (LDD™s), representing a 208% unit incr